| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
L-Methionine-d3 targets endogenous metabolic pathways involving methionine metabolism. L-Methionine itself plays roles in purine and pyrimidine synthesis, polyamine synthesis, and glutathione production. The compound is used to study metabolic diseases such as homocystinuria and cardiovascular disease.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
L-Methionine can inhibit cell proliferation and induce cell apoptosis, and exhibits antitumor and antioxidant activity. Studies demonstrate that the deuterated form is comparably active to non-deuterated methionine in certain enzymatic transformations, indicating that deuteration does not hinder enzyme-substrate interactions. |
| ln Vivo |
Stable heavy isotopes such as deuterium have been incorporated into drug molecules largely as tracers for quantitation during drug development. Deuteration may affect the pharmacokinetic and metabolic profiles of drugs. The compound is used in metabolic tracing studies to elucidate methionine-related pathways.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for L-Methionine-d3 typically involve incubation with relevant enzymes (e.g., methionine adenosyltransferase) in buffered solutions at physiological pH. Enzyme activity is measured by monitoring the conversion of methionine to its metabolites using LC-MS or radiometric detection. The deuterated form serves as an internal standard to correct for matrix effects and ionization efficiency variations. Binding affinity and kinetic parameters (Km, Vmax) are determined by varying substrate concentrations and analyzing reaction rates.
|
| Cell Assay |
For in vitro cell assays, cells are cultured in methionine-free medium supplemented with L-Methionine-d3 at concentrations ranging from 0.1 to 10 mM. After incubation for 24-72 hours, cell proliferation is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by flow cytometry using Annexin V-FITC/PI staining. Cellular uptake and metabolism of the labeled methionine are analyzed by LC-MS/MS to track deuterium incorporation into intracellular metabolites and proteins.
|
| Animal Protocol |
For in vivo animal studies, L-Methionine-d3 is typically administered to rodents via oral gavage or intraperitoneal injection at doses of 50-200 mg/kg. Blood and tissue samples are collected at various time points (0-24 hours). Plasma and tissue methionine levels are quantified by LC-MS/MS using the deuterated compound as an internal standard. Metabolic flux analysis is performed to trace the incorporation of deuterium into downstream metabolites such as homocysteine, cysteine, and glutathione.
|
| ADME/Pharmacokinetics |
L-Methionine-d3 exhibits good water solubility (>20 mg/mL). As a stable isotope-labeled compound, it has identical physicochemical properties to unlabeled L-methionine, with the deuterium atoms providing a mass shift of +3 Da for MS detection. The compound is stable under recommended storage conditions (powder at -20°C for 3 years, in solvent at -80°C for 6 months). It is absorbed via amino acid transporters and metabolized through the methionine cycle.
|
| Toxicity/Toxicokinetics |
L-Methionine is generally recognized as safe at physiological concentrations. The deuterated form is not expected to exhibit additional toxicity beyond that of L-methionine. In animal studies, high doses of methionine (>1 g/kg) may cause hypermethioninemia and neurological effects. The compound is for research use only and has not been fully validated for medical applications. No specific toxicity data are available for the deuterated analog; safety profiles are extrapolated from the non-labeled compound.
|
| References | |
| Additional Infomation |
L-methionine-d3 is a deuterated compound of L-methionine.
L-Methionine-d3 (CAS# 13010-53-2) is a stable isotope-labeled compound used primarily as an analytical internal standard. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is widely used in metabolic research, nutritional studies, and pharmaceutical development. Deuteration does not alter the fundamental biological activity of methionine but enables precise quantification in complex biological matrices. |
| Molecular Formula |
C5H8D3NO2S
|
|---|---|
| Molecular Weight |
152.23
|
| Exact Mass |
152.069
|
| CAS # |
13010-53-2
|
| Related CAS # |
L-Methionine;63-68-3
|
| PubChem CID |
15556503
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
306.9±37.0 °C at 760 mmHg
|
| Melting Point |
273ºC (dec.)(lit.)
|
| Flash Point |
139.4±26.5 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.531
|
| LogP |
0.37
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
97
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C([2H])([2H])SCC[C@@H](C(=O)O)N
|
| InChi Key |
FFEARJCKVFRZRR-OSIBIXDNSA-N
|
| InChi Code |
InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1/i1D3
|
| Chemical Name |
(2S)-2-amino-4-(trideuteriomethylsulfanyl)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 20 mg/mL (131.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5690 mL | 32.8450 mL | 65.6901 mL | |
| 5 mM | 1.3138 mL | 6.5690 mL | 13.1380 mL | |
| 10 mM | 0.6569 mL | 3.2845 mL | 6.5690 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
